New perspectives in the renin-angiotensin-aldosterone system (RAAS) IV: Circulating ACE2 as a biomarker of systolic dysfunction in human hypertension and heart failure

PLoS ONE

Volumn 9, Issue 4, 2014, Pages

  Úri, Katalin ^a   Fagyas, Miklós ^a   Siket, Ivetta Mányiné ^a   Kertész, Attila ^b   Csanádi, Zoltán ^b   Sándorfi, Gábor ^b   Clemens, Marcell ^b   Fedor, Roland ^b   Papp, Zoltán ^a,b   Édes, István ^b   Tóth, Attila ^a,b   Lizanecz, Erzsébet ^b  

^a UNIVERSITY OF DEBRECEN   (Hungary)

^b UNIVERSITY OF DEBRECEN   (Hungary)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; ANGIOTENSIN CONVERTING ENZYME 2; BIOLOGICAL MARKER; BRAIN NATRIURETIC PEPTIDE; DIPEPTIDYL CARBOXYPEPTIDASE; PEPTIDE FRAGMENT; PRO-BRAIN NATRIURETIC PEPTIDE (1-76);

ADULT; ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME BLOOD LEVEL; ENZYME LOCALIZATION; FEMALE; HEART LEFT VENTRICLE CONTRACTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE ENDDIASTOLIC VOLUME; HEART LEFT VENTRICLE ENDSYSTOLIC VOLUME; HEART VENTRICLE SIZE; HUMAN; MALE; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SYSTOLIC HEART FAILURE; SYSTOLIC HYPERTENSION; BLOOD; ECHOGRAPHY; ENZYMOLOGY; HEART FAILURE; HEART STROKE VOLUME; HEART VENTRICLE REMODELING; HYPERTENSION; METABOLISM; MIDDLE AGED; PATHOPHYSIOLOGY; SYSTOLE;

ADULT; BIOMARKERS; FEMALE; HEART FAILURE; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS; PEPTIDYL-DIPEPTIDASE A; RENIN-ANGIOTENSIN SYSTEM; STROKE VOLUME; SYSTOLE; VENTRICULAR REMODELING;

EID: 84898888351     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0087845     Document Type: Article

References (36)

1. Nicholls MG, Richards AM, Agarwal M (1998) The importance of the renin-angiotensin system in cardiovascular disease. J Hum Hypertens 12: 295-299. (Pubitemid 28274359)
2. Ferrario CM (1990) The renin-angiotensin system: importance in physiology and pathology. J Cardiovasc Pharmacol 15 Suppl 3: S1-5.
3. Donoghue M, Hsieh F, Baronas E, Godbout K, Gosselin M, et al. (2000) A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9. Circ Res 87: E1-9.
4. Santos RA, Simoes e Silva AC, Maric C, Silva DM, Machado RP, et al. (2003) Angiotensin-(1-7) is an endogenous ligand for the G protein-coupled receptor Mas. Proc Natl Acad Sci U S A 100: 8258-8263. (Pubitemid 36842532)
5. Zhong J, Basu R, Guo D, Chow FL, Byrns S, et al. (2010) Angiotensin-converting enzyme 2 suppresses pathological hypertrophy, myocardial fibrosis, and cardiac dysfunction. Circulation 122: 717-728, 718 p following 728.
6. Kostenis E, Milligan G, Christopoulos A, Sanchez-Ferrer CF, Heringer-Walther S, et al. (2005) G-protein-coupled receptor Mas is a physiological antagonist of the angiotensin II type 1 receptor. Circulation 111: 1806-1813. (Pubitemid 40525146)
7. Gallagher PE, Ferrario CM, Tallant EA (2008) Regulation of ACE2 in cardiac myocytes and fibroblasts. Am J Physiol Heart Circ Physiol 295: H2373-2379.
8. Epelman S, Shrestha K, Troughton RW, Francis GS, Sen S, et al. (2009) Soluble angiotensin-converting enzyme 2 in human heart failure: relation with myocardial function and clinical outcomes. J Card Fail 15: 565-571.
9. Lambert DW, Yarski M, Warner FJ, Thornhill P, Parkin ET, et al. (2005) Tumor necrosis factor-alpha convertase (ADAM17) mediates regulated ectodomain shedding of the severe-acute respiratory syndrome-coronavirus (SARS-CoV) receptor, angiotensin-converting enzyme-2 (ACE2). J Biol Chem 280: 30113-30119. (Pubitemid 41216188)
10. Wang W, Bodiga S, Das SK, Lo J, Patel V, et al. (2012) Role of ACE2 in diastolic and systolic heart failure. Heart Fail Rev 17: 683-691.
11. Rentzsch B, Todiras M, Iliescu R, Popova E, Campos LA, et al. (2008) Transgenic angiotensin-converting enzyme 2 overexpression in vessels of SHRSP rats reduces blood pressure and improves endothelial function. Hypertension 52: 967-973.
12. Yamazato M, Yamazato Y, Sun C, Diez-Freire C, Raizada MK (2007) Overexpression of angiotensin-converting enzyme 2 in the rostral ventrolateral medulla causes long-term decrease in blood pressure in the spontaneously hypertensive rats. Hypertension 49: 926-931. (Pubitemid 351664196)
13. Gurley SB, Allred A, Le TH, Griffiths R, Mao L, et al. (2006) Altered blood pressure responses and normal cardiac phenotype in ACE2-null mice. J Clin Invest 116: 2218-2225. (Pubitemid 44162331)
14. Wysocki J, Ye M, Rodriguez E, Gonzalez-Pacheco FR, Barrios C, et al. (2010) Targeting the degradation of angiotensin II with recombinant angiotensin-converting enzyme 2: prevention of angiotensin II-dependent hypertension. Hypertension 55: 90-98.
15. Zhong J, Yan Z, Liu D, Ni Y, Zhao Z, et al. (2006) Association of angiotensin-converting enzyme 2 gene A/G polymorphism and elevated blood pressure in Chinese patients with metabolic syndrome. J Lab Clin Med 147: 91-95. (Pubitemid 43189001)
16. Lu N, Yang Y, Wang Y, Liu Y, Fu G, et al. (2012) ACE2 gene polymorphism and essential hypertension: an updated meta-analysis involving 11,051 subjects. Mol Biol Rep 39: 6581-6589.
17. Patel SK, Wai B, Ord M, MacIsaac RJ, Grant S, et al. (2012) Association of ACE2 genetic variants with blood pressure, left ventricular mass, and cardiac function in Caucasians with type 2 diabetes. Am J Hypertens 25: 216-222.
18. Der Sarkissian S, Huentelman MJ, Stewart J, Katovich MJ, Raizada MK (2006) ACE2: A novel therapeutic target for cardiovascular diseases. Progress in Biophysics & Molecular Biology 91: 163-198. (Pubitemid 43288989)
19. Bodiga S, Zhong JC, Wang W, Basu R, Lo J, et al. (2011) Enhanced susceptibility to biomechanical stress in ACE2 null mice is prevented by loss of the p47(phox) NADPH oxidase subunit. Cardiovasc Res 91: 151-161.
20. Goulter AB, Goddard MJ, Allen JC, Clark KL (2004) ACE2 gene expression is up-regulated in the human failing heart. BMC Med 2: 19.
21. Yamamoto K, Ohishi M, Katsuya T, Ito N, Ikushima M, et al. (2006) Deletion of angiotensin-converting enzyme 2 accelerates pressure overload-induced cardiac dysfunction by increasing local angiotensin II. Hypertension 47: 718-726. (Pubitemid 43740244)
22. Lehmann HI, Wolke C, Malenke W, Rohl FW, Hammwohner M, et al. (2012) Enzymatic activity of DPIV and renin-angiotensin system (RAS) proteases in patients with left ventricular dysfunction and primary prevention implantable cardioverter/defibrillator (ICD). Int J Cardiol.
23. Dickstein K, Cohen-Solal A, Filippatos G, McMurray JJ, Ponikowski P, et al. (2008) ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur Heart J 29: 2388-2442.
24. Dickstein K, Vardas PE, Auricchio A, Daubert JC, Linde C, et al. (2010) 2010 Focused Update of ESC Guidelines on device therapy in heart failure: an update of the 2008 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure and the 2007 ESC guidelines for cardiac and resynchronization therapy. Developed with the special contribution of the Heart Failure Association and the European Heart Rhythm Association. Eur Heart J 31: 2677-2687.
25. Vickers C, Hales P, Kaushik V, Dick L, Gavin J, et al. (2002) Hydrolysis of biological peptides by human angiotensin-converting enzyme-related carboxypeptidase. J Biol Chem 277: 14838-14843. (Pubitemid 34952556)
26. Epelman S, Tang WH, Chen SY, Van Lente F, Francis GS, et al. (2008) Detection of soluble angiotensin-converting enzyme 2 in heart failure: insights into the endogenous counter-regulatory pathway of the renin-angiotensin- aldosterone system. J Am Coll Cardiol 52: 750-754.
27. Patel SK, Velkoska E, Burrell LM (2013) Emerging markers in cardiovascular disease: where does ACE2 fit in? Clin Exp Pharmacol Physiol.
28. Ronca-Testoni S (1983) Direct spectrophotometric assay for angiotensin-converting enzyme in serum. Clin Chem 29: 1093-1096.
29. Beneteau B, Baudin B, Morgant G, Giboudeau J, Baumann FC (1986) Automated kinetic assay of angiotensin-converting enzyme in serum. Clin Chem 32: 884-886. (Pubitemid 17028376)
30. Fagyas M, Úri K, Mányiné IS, Daragó A, Boczán J, et al. (2014) New perspectives in the renin-angiotensin- aldosterone system (RAAS) III: endogenous inhibition of angiotensin converting enzyme (ACE) provides protection against cardiovascular diseases. PLoS One.
31. Fagyas M, Úri K, Mányiné IS, Daragó A, Boczán J, et al. (2014) New perspectives in the renin-angiotensin- aldosterone system (RAAS) I: endogenous angiotensin converting enzyme (ACE) inhibition. PLoS One.
32. Fagyas M, Úri K, Mányiné IS, Fülöp GÁ, Csató V, et al. (2014) New perspectives in the renin-angiotensin-aldosterone system (RAAS) II: albumin suppresses angiotensin converting enzyme (ACE) activity in human. PLoS One.
33. Crackower MA, Sarao R, Oudit GY, Yagil C, Kozieradzki I, et al. (2002) Angiotensin-converting enzyme 2 is an essential regulator of heart function. Nature 417: 822-828. (Pubitemid 34670323)
34. Burrell LM, Risvanis J, Kubota E, Dean RG, MacDonald PS, et al. (2005) Myocardial infarction increases ACE2 expression in rat and humans. Eur Heart J 26: 369-375; discussion 322-364.
35. van Kimmenade RR, Januzzi JL Jr. (2012) Emerging biomarkers in heart failure. Clin Chem 58: 127-138.
36. Tang WH, Francis GS (2007) Cardiac resynchronization therapy in New York Heart Association class IV heart failure: it is all about selection. Circulation 115: 161-162. (Pubitemid 46105713)